Skip to main content

Hereditary Angioedema Types I and II

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
NCT01576523 | PHASE 1 | INTERVENTIONAL

The aim of the study is to assess what happens to C1-esterase inhibitor that is administered under the skin of subjects with hereditary angioedema. Three different dosing regimens of C1-esterase inhibitor will be assessed. Each subject will be assigned to receive 2 of the 3 dosing regimens, each for 4 weeks. The activity and concentration of C1-esterase inhibitor in the blood will be measured during each 4-week period. The study will also examine how well C1-esterase inhibitor administered under the skin is tolerated by the subjects.

Trial Information
8 Sites
18 Participants
Recruiting
18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Atlanta,Georgia,United States,30342
Study Site
Chevy Chase,Maryland,United States,20815
Study Site
Cincinnati,Ohio,United States,45231
Study Site
Toledo,Ohio,United States,43617
Study Site
Hershey,Pennsylvania,United States,19108
Study Site
Berlin,Germany,10117
Study Site
Frankfurt,Germany,60596
Study Site
Mainz,Germany,55101

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov